HealthEquity (HQY)
(Delayed Data from NSDQ)
$78.91 USD
-1.39 (-1.73%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $78.91 0.00 (0.00%) 7:52 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$78.91 USD
-1.39 (-1.73%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $78.91 0.00 (0.00%) 7:52 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Zacks News
Here's Why You Should Hold on to Accuray (ARAY) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Accuray (ARAY) owing to its solid global reach.
Catalent (CTLT) Inks Deal With MigVax for Oral COVID-19 Vaccine
by Zacks Equity Research
Catalent's (CTLT) latest agreement is expected to significantly boost global COVID-19 vaccination drives.
BD's (BDX) New Tie-Up to Develop Detection Kit for Monkeypox
by Zacks Equity Research
BD's (BDX) partnership with CerTest is expected to aid in advancing the understanding of the monkeypox virus' global spread.
BD (BDX) to Expand Base in Pharmacy Automation With New Buyout
by Zacks Equity Research
BD's (BDX) buyout of Parata Systems is expected to advance its 2025 strategy to accelerate innovation in smart, connected care and enabling new care settings.
HealthEquity (HQY) Q1 Earnings Lag Estimates, FY23 View Up
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust segmental revenues, in the first quarter of fiscal 2023.
Here's Why You Should Hold on to Avanos (AVNS) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.
HealthEquity (HQY) Q1 Earnings Miss Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of -3.57% and 1.46%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?
Assure Holdings Corp. (IONM) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Assure Holdings Corp. (IONM) delivered earnings and revenue surprises of -216.67% and 27.68%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 6.67% and 67.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
InnovAge Holding Corp. (INNV) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
InnovAge Holding Corp. (INNV) delivered earnings and revenue surprises of -300% and 5.40%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) Q1 Earnings Beat Estimates
by Zacks Equity Research
Viatris (VTRS) delivered earnings and revenue surprises of 14.81% and 0.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
HealthEquity (HQY) Q4 Earnings Lag Estimates, Margins Down
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, along with recording robust Custodial and Interchange revenues, in the fourth quarter of fiscal 2022.
HealthEquity (HQY) Q4 Earnings Miss Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of -4.76% and 2.02%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: HealthEquity (HQY) Q4 Earnings Expected to Decline
by Zacks Equity Research
HealthEquity (HQY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DermTech, Inc. (DMTK) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
DermTech, Inc. (DMTK) delivered earnings and revenue surprises of -20.55% and 5.97%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
GoodRx Holdings, Inc. (GDRX) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) delivered earnings and revenue surprises of -10% and 1.57%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
ModivCare (MODV) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
ModivCare (MODV) delivered earnings and revenue surprises of 28.66% and 4.12%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Abbott (ABT) Gets FDA Approval for CardioMEMS HF System
by Zacks Equity Research
Abbott's (ABT) CardioMEMS HF System will enable physicians to monitor for early warning signs of worsening heart failure before it progresses to a later stage.
Here's Why You Should Hold on to STERIS (STE) Stock for Now
by Zacks Equity Research
Investors are optimistic about STERIS (STE) on its better-than-expected earnings in the fiscal third quarter and the ongoing integration of the Cantel Medical business.
Here's Why You Should Hold on to IDEXX (IDXX) Stock for Now
by Zacks Equity Research
Robust domestic and international performances by the CAG arm are driving IDEXX's (IDXX) fourth-quarter top line.
Tandem Diabetes (TNDM) to Offer Insulin Delivery With Smartphone
by Zacks Equity Research
Tandem Diabetes' (TNDM) t:connect is the first-ever app on both iOS and Android operating systems to receive FDA clearance for insulin delivery from a personal smartphone.
OPKO's (OPK) NGENLA to Offer GHD Treatment in European Union
by Zacks Equity Research
OPKO's (OPK) marketing authorization for NGENLA in the European Union stands to benefit children and adolescents affected by growth hormone deficiency.
Here's Why You Should Hold on to Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Investors are optimistic about Thermo Fisher's (TMO) better-than-expected fourth-quarter results and impressive COVID-19 response-related revenues.
HealthEquity (HQY) Up 10.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for December 21st
by Zacks Equity Research
BLBD, CBRL, HQY, LE and PHX have been added to the Zacks Rank #5 (Strong Sell) List on December 21, 2021.